{"drugs":["Golimumab","Simponi","Simponi Aria"],"mono":{"0":{"id":"929360-s-0","title":"Generic Names","mono":"Golimumab"},"1":{"id":"929360-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929360-s-1-4","title":"Adult Dosing","mono":"<ul><li>(Simponi(R), Simponi(R) Aria(TM)) prior to initiation of golimumab therapy, evaluate patients for active TB and test for latent TB and hepatitis B viral infection; repeat TB monitoring periodically during therapy<\/li><li><b>Ankylosing spondylitis, Active:<\/b> (Simponi(R)) 50 mg SUBQ once monthly.<\/li><li><b>Psoriatic arthritis, Active, alone, or in combination with methotrexate:<\/b> (Simponi(R)) 50 mg SUBQ once monthly<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), Active, in combination with methotrexate:<\/b> (Simponi(R), Aria(TM)) 2 mg\/kg IV infusion over 30 minutes at weeks 0 and 4, then every 8 weeks in combination with methotrexate<\/li><li><b>Rheumatoid arthritis (Moderate to Severe), Active, in combination with methotrexate:<\/b> (Simponi(R)) 50 mg SUBQ once monthly in combination with methotrexate<\/li><li><b>Ulcerative colitis (Moderate to Severe), Active:<\/b> (Simponi(R)) induction, 200 mg SUBQ at week 0, followed by 100 mg SUBQ at week 2, then maintenance, 100 mg SUBQ every 4 weeks<\/li><\/ul>"},"1":{"id":"929360-s-1-5","title":"Pediatric Dosing","mono":"Safety and effectiveness of golimumab have not been established in pediatric patients "},"3":{"id":"929360-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Ankylosing spondylitis, Active<\/li><li>Psoriatic arthritis, Active, alone, or in combination with methotrexate<\/li><li>Rheumatoid arthritis (Moderate to Severe), Active, in combination with methotrexate<\/li><li>Ulcerative colitis (Moderate to Severe), Active<\/li><\/ul>"}}},"2":{"id":"929360-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Solution)<\/b><br\/>Serious infections leading to hospitalization or death, including TB, bacterial sepsis, invasive fungal (eg, histoplasmosis), and other opportunistic infections have occurred in patients receiving golimumab. Discontinue golimumab if a patient develops a serious infection or sepsis. Perform test for latent TB; if positive, start treatment for TB prior to starting golimumab. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, of which golimumab is a member.<br\/><\/li><li><b>Subcutaneous (Solution)<\/b><br\/>Serious infections leading to hospitalization or death, including TB, bacterial sepsis, invasive fungal (eg, histoplasmosis), and other opportunistic infections have occurred in patients receiving golimumab. Discontinue golimumab if a patient develops a serious infection or sepsis. Perform test for latent TB; if positive, start treatment for TB prior to starting golimumab. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, of which golimumab is a member.<br\/><\/li><\/ul>"},"3":{"id":"929360-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929360-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"929360-s-3-10","title":"Precautions","mono":"<ul><li>serious infections (eg, bacterial [including Legionella and Listeria], TB, invasive fungal infections, viral, parasitic, and other opportunistic infections), including fatalities, have been reported with the use of tumor necrosis factor (TNF) blockers; increased risk in elderly, patients with comorbidities, concomitant immunosuppressant therapy or switching from another biological disease modifying antirheumatic drug, chronic or recurrent infection, history of opportunistic infection, or travel\/residence in endemic regions; do not initiate therapy in patients with active infections (including clinically relevant localized infections); monitoring recommended in all patients; therapy discontinuation may be required<\/li><li>TB, reactivation or new-onset, has occurred with the use of TNF blockers; increased risk in patients with potential exposure due to travel or residence in endemic areas, close personal contact with active TB, or with history of latent or active disease, regardless of previous BCG vaccination; treatment of infection prior to TNF therapy may reduce risk of reactivation; monitoring recommended<\/li><li>children, adolescents, and young adults who initiate therapy before the age of 18 years; lymphoma and other malignancies, including fatalities, have been reported with TNF blockers (golimumab not indicated in pediatric population)<\/li><li>malignancies, including increased incidence of lymphomas and reports of leukemia, melanoma, and Merkel cell carcinoma, have been reported with TNF blocker use; monitoring recommended; evaluate risk\/benefit before starting therapy in patients with known malignancy (except successfully treated non-melanoma skin cancer)<\/li><li>auto-antibody formation, including development of a lupus-like syndrome, has occurred with TNF blocker use<\/li><li>concomitant use of abatacept, anakinra, or biologics used to treat rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis is not recommended<\/li><li>concomitant use of live vaccines or therapeutic infectious agents containing live attenuated bacteria is not recommended<\/li><li>congestive heart failure, new onset or worsening of preexisting disease, has been reported; monitoring recommended; therapy discontinuation may be required<\/li><li>demyelinating disorders, new onset or worsening of CNS or peripheral disorders (eg, multiple sclerosis, Guillain-Barr  syndrome, optic neuritis) have been reported with TNF blockers; therapy discontinuation may be required<\/li><li>hematologic cytopenias (leukopenia, neutropenia, thrombocytopenia, and pancytopenia) have been reported with TNF blockers<\/li><li>hepatitis B virus, chronic carriers; reactivation, including fatalities, has occurred with the use of TNF blockers; monitoring recommended; discontinuation and supportive treatment may be necessary<\/li><li>hepatosplenic T-cell lymphoma has been reported primarily in adolescents and young adults receiving TNF blockers for Crohn disease or ulcerative colitis; most cases were fatal and occurred with concomitant use of azathioprine or mercaptopurine; carefully assess risk\/benefit of using TNF blockers<\/li><li>hypersensitivity reactions, including anaphylaxis, have been reported<\/li><li>latex sensitivity; allergic reactions may occur in latex-sensitive patients; needle cover of prefilled syringe and autoinjector prefilled syringe contain dry natural rubber, a latex derivative<\/li><li>patients at risk for dysplasia or colon cancer; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929360-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"929360-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929360-s-4","title":"Drug Interactions","sub":{"1":{"id":"929360-s-4-14","title":"Major","mono":"<ul><li>Abatacept (theoretical)<\/li><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Aminophylline (theoretical)<\/li><li>Anakinra (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Bacillus of Calmette and Guerin (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><\/ul>"}}},"5":{"id":"929360-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension (3%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction (SubQ, 3.4% to 6%), Rash (IV, 3%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (Up to 4%), AST\/SGOT level raised (3%)<\/li><li><b>Immunologic:<\/b>Viral disease (4% to 5%)<\/li><li><b>Neurologic:<\/b>Dizziness (Up to 2%), Paresthesia (Up to 2%)<\/li><li><b>Respiratory:<\/b>Bronchitis (2% to 3%), Sinusitis (Up to 2%), Upper respiratory infection (13% to 16%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure<\/li><li><b>Dermatologic:<\/b>Malignant melanoma, Merkel cell carcinoma, Sarcoidosis, Skin cancer, Non-melanoma<\/li><li><b>Hepatic:<\/b>Hepatitis B, Reactivation<\/li><li><b>Immunologic:<\/b>Lupus erythematosus and erythema multiforme-like syndrome, Malignant lymphoma, Mycosis, Invasive, Opportunistic infection, Tuberculosis<\/li><li><b>Neurologic:<\/b>Demyelinating disease of central nervous system, Guillain-Barr  syndrome, Peripheral demyelinating neuropathy<\/li><li><b>Ophthalmic:<\/b>Optic neuritis<\/li><li><b>Respiratory:<\/b>Legionella pneumonia, Pneumonia (Less than 1%)<\/li><li><b>Other:<\/b>Cancer, Infectious disease (12% to 28%; serious, 0.9% to 1.4%), Legionella pneumonia, Listeriosis<\/li><\/ul>"},"6":{"id":"929360-s-6","title":"Drug Name Info","sub":{"0":{"id":"929360-s-6-17","title":"US Trade Names","mono":"<ul><li>Simponi<\/li><li>Simponi Aria<\/li><\/ul>"},"2":{"id":"929360-s-6-19","title":"Class","mono":"<ul><li>Immune Modulator<\/li><li>Monoclonal Antibody<\/li><li>Tumor Necrosis Factor Inhibitor<\/li><\/ul>"},"3":{"id":"929360-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929360-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929360-s-7","title":"Mechanism Of Action","mono":"Tumor necrosis factor (TNF) is a naturally occurring cytokine that is involved with inflammatory and immune responses. Golimumab is a human monoclonal antibody that binds to both soluble and transmembrane bioactive forms of human TNF alfa, resulting in inhibition of TNF alfa activity associated with several chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The exact mechanism for the action of golimumab in ulcerative colitis is unknown.<br\/>"},"8":{"id":"929360-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929360-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, subQ: 2 to 6 days<\/li><li>Steady state, subQ: 12 weeks<\/li><li>Bioavailability, subQ: approximately 53%<\/li><\/ul>"},"1":{"id":"929360-s-8-24","title":"Distribution","mono":"Vd: 58 to 126 mL\/kg <br\/>"},"3":{"id":"929360-s-8-26","title":"Excretion","mono":"Total body clearance: 4.9 to 6.7 mL\/day\/kg <br\/>"},"4":{"id":"929360-s-8-27","title":"Elimination Half Life","mono":"Approximately 2 weeks <br\/>"}}},"9":{"id":"929360-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>Simponi(R) Aria(TM) do not use if discoloration or opaque or foreign articles are present<\/li><li>Simponi(R) Aria(TM) dilute calculated golimumab dose in NS to a total infusional volume of 100 mL<\/li><li>Simponi(R) Aria(TM) infuse over 30 minutes through inline filter (0.22-micron or less)<\/li><li>Simponi(R) Aria(TM) do not infuse concomitantly with other agents<\/li><li>Simponi(R) Aria(TM) diluted infusion solution may be stored for up to 4 hours at room temperature<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Simponi(R) allow prefilled syringe or SmartJect(R) autoinjector device to sit at room temperature for 30 minutes prior to subQ injection; do not warm any other way<\/li><li>Simponi(R) prefilled syringe and SmartJect(R) autoinjector device contain latex (dry natural rubber)<\/li><li>Simponi(R) do not use leftover drug<\/li><li>Simponi(R) rotate the injection site; if multiple injections are needed, use different body sites<\/li><li>Simponi(R) avoid injection where the skin is tender, red, bruised, or hard<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929360-s-10","title":"Monitoring","mono":"<ul><li>Ankylosing spondylitis: normalization of serum C-reactive protein levels and reduction in signs and symptoms indicate efficacy<\/li><li>Psoriatic arthritis: normalization of serum C-reactive protein levels, reduction in signs and symptoms and improved physical function indicate efficacy<\/li><li>Rheumatoid arthritis: normalization of serum C-reactive protein levels, reduction in signs and symptoms and improved physical function indicate efficacy<\/li><li>Ulcerative colitis: improvement in signs and symptoms indicates efficacy<\/li><li>CBC; before and during therapy<\/li><li>Active and latent TB; prior to and periodically during therapy, including patients who had a negative tuberculin test prior to treatment initiation or who previously received treatment for latent or active TB<\/li><li>Infection; during and after treatment<\/li><li>Hepatitis B virus (HBV) infection; evaluate for infection and carrier status prior to therapy; laboratory and clinical signs of HBV in carriers throughout therapy and for several months following discontinuation<\/li><li>Dysplasia; in patients with ulcerative colitis at risk for dysplasia or colon carcinoma before and during therapy<\/li><li>Skin cancer; periodically in all patients, especially those with risk factors<\/li><li>Congestive heart failure; new or worsening symptoms during therapy<\/li><\/ul>"},"11":{"id":"929360-s-11","title":"How Supplied","mono":"<ul><li><b>Simponi Aria<\/b><br\/>Intravenous Solution: 50 MG\/4 ML<br\/><\/li><li><b>Simponi<\/b><br\/>Subcutaneous Solution: 50 MG\/0.5 ML, 100 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"929360-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient on the increased risk of infection and to report signs\/symptoms of an infection or a recurring infection (hepatitis B, TB) during therapy  and for several months after discontinuation.<\/li><li>Advise patient of increased risk of lymphoma and other malignancies  and to report persistent fevers, night sweats, or significant weight loss.<\/li><li>Warn patient to avoid live vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Instruct patient to report a latex sensitivity prior to use, as needle cover of prefilled syringe contains dry natural rubber (latex derivative).<\/li><li>Side effects may include upper respiratory infections, hypertension, rash, dizziness, and injection site reactions if given subQ.<\/li><li>Advise patient to report symptoms of new or worsening congestive heart failure, demyelinating disorders, autoimmune diseases, liver disease, cytopenias, or psoriasis.<\/li><li>Counsel patient about proper injection sites and rotation if administering subQ.<\/li><\/ul>"}}}